CD8A and neoplasm: Anticancer immunotherapies may also be reduced by TAM when their suppression of TME correlates with an increase of DC-vaccination therapy in a malignant mesothelioma mouse model [83] or an increase of anti-PD1 treatment favoring CD8 T cells recruitment to the tumor site [84,85].